JPRN-UMIN000037280已完成2 期
Phase II study on biweekly combination therapy of gemcitabine plus carboplatin for the treatment of elderly patient with advanced non-small cell lung cancer - LOGIK0406
Clinical Research Support Center Kyushu0 个研究点目标入组 48 人开始时间: 2019年7月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
ORR: 29.2%(95%CI: 17.0-44.1) PFS: 178days(95%CI 122-198) OS: 398days
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients with obvious infections (2) Patients with fever (38C or higher) (3) Serious complications (heart disease, pulmonary fibrosis/interstitial pneumonia, bleeding tendency, uncontrolled) Patients with hypertension, diabetes mellitus, etc. (4) Patients with active double cancer (disease-free interval <5 years) (5) Symptomatic patients with brain metastases (6) Patients with pleural effusions and ascites requiring treatment (7) Patients with pericardial effusion (8) Patients with varicella (9) Patients with motor paralysis or peripheral nerve symptoms (excluding those originating from the primary disease) (10) Patients with a history of drug hypersensitivity (11) Pregnant, breastfeeding, and women of childbearing potential (willingness) (12) Other patients judged inappropriate by the investigator
研究者
相似试验
已完成
不适用
A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602)Colorectal CancerJPRN-UMIN000025241Kyushu Study group of Clinical Cancer39
已完成
2 期
Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000008145Kyoto Prefectural University of Medicine/K-LSG33
已完成
2 期
A phase II study to evaluate the effectiveness of l-LV/5-FU (mRPMI regimen) + Bevacizumab for patients with advanced/recurrent colon cancer who cannot undergo common protocol (OGSG 0802)JPRN-UMIN000002182Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)41
招募中
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumorocally recurrent or metastatic breast cancer patients with HER2/neu negative tumorNL-OMON20125VU University medical centerProf. E. Boven, MD, PhD, medical oncologistDe Boelelaan 11171081 HV AmsterdamPhone: 020-444 4336E-mail: e.boven@vumc.nltogether with:Borstkanker Onderzoek Groep(BOOG) Dr. A.E. van Leeuwen-Stok, research-managerP.O. Box 9236, 1006 AE AmsterdamPhone: 020-346 2547Fax: 020-346 2525E-mail: boog@ikca.nl312
已完成
2 期
A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602)Colorectal CancerJPRN-jRCTs071180065Oki Eiji39